Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: September 06, 2022
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Journal: Blood
Published: December 17, 2020
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Journal: BMC cancer
Published: September 29, 2020
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: November 04, 2019
Publisher Correction: Novel multiplex PCR-SSP method for centromeric KIR allele discrimination.
Journal: Scientific reports
Published: October 20, 2019
Novel multiplex PCR-SSP method for centromeric KIR allele discrimination.
Journal: Scientific reports
Published: May 25, 2018
Showing 1-7 of 7
Last Updated: 09/26/2026